CAPR_OUT_1 [2025-03-20 14:30:08 -0400] 2073 Bytes | 597 tokens | Cum: 597 tkns (7.46% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Capricor Therapeutics (CAPR) hit my radar screen, up to 14.69 from a prev close of 12.22 Do you think its got more juice or is it lacking potential? It's 02:30:06 PM on Thursday March 20, 2025 ET (UTC-0400) and I have to decide: buy or sell!

Here's the first list of news for Capricor Therapeutics:

C1 - Today 10:21AM - Q4 2024 Capricor Therapeutics Inc Earnings Call
C2 - Mar-19-25 06:57PM - Capricor projects FDA priority review decision for deramiocel by August 2025
C3 - Mar-19-25 06:57PM 06:56PM - Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript
C4 - Mar-19-25 06:57PM 05:15PM - Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates
C5 - Mar-19-25 06:57PM 04:17PM - Capricor: Q4 Earnings Snapshot
C6 - Mar-19-25 06:57PM 04:05PM - Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
C7 - Mar-18-25 09:31AM - Capricor Therapeutics announces long-term data from HOPE-2 OLE study
C8 - Mar-17-25 09:25AM - Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Capricor Therapeutics (CAPR)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CAPR_OUT_3 [2025-03-20 14:30:13 -0400] 692 Bytes | 213 tokens | Cum: 812 tkns (10.15% of 8k)
==========================================================================

Showing C2 (chunk 1 of 1): C2:
**Capricor projects FDA priority review decision for deramiocel by August 2025**
Date: Mar-19-25 06:57PM
Source: (SeekingAlpha)
URL: https://seekingalpha.com/news/4422592-capricor-projects-fda-priority-review-decision-for-deramiocel-by-august-2025?utm_source=finviz.com&utm_medium=referral&feed_item_type=news

Error fetching article: 403 Client Error: Forbidden for url: https://seekingalpha.com/news/4422592-capricor-projects-fda-priority-review-decision-for-deramiocel-by-august-2025?utm_source=finviz.com&utm_medium=referral&feed_item_type=news

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CAPR_OUT_5 [2025-03-20 14:30:14 -0400] 917 Bytes | 285 tokens | Cum: 1158 tkns (14.47% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T14:43:39Z - Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big S...
A2 - 2025-03-20T10:23:51Z - Capricor Therapeutics Stock (CAPR) Surges on Q4 Results and Promising New Therapy...
A3 - 2025-03-20T12:02:11Z - A Glimpse Into The Expert Outlook On Capricor Therapeutics Through 4 Analysts - Capricor Therapeutic...
A4 - 2025-03-19T22:56:54Z - Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript...
A5 - 2025-03-19T20:53:32Z - Capricor: Q4 Earnings Snapshot...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CAPR_OUT_7 [2025-03-20 14:30:15 -0400] 1038 Bytes | 278 tokens | Cum: 1438 tkns (17.97% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - China Liberal Education (NASDAQ:CLEU), Capricor Therapeutics (NASDAQ:CAPR)**Date: 2025-03-20Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/03/44418649/jabil-posts-better-than-expected-earnings-joins-darden-restaurants-qxo-five-below-and-other-big-stocks-moving-higher-on-thursdayU.S. stocks were higher, with the Dow Jones index gaining around 100 points on Thursday.

Shares of Jabil Inc. JBL rose sharply during Wednesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 guidance.

Jabil reported second-quarter adjusted earnings per share of $1.94, beating the analyst consensus estimate of $1.83. Quarterly sales of $6.73 billion outpac

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CAPR_OUT_9 [2025-03-20 14:30:23 -0400] 1038 Bytes | 292 tokens | Cum: 1732 tkns (21.65% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): ed the analyst consensus estimate of $6.408 billion.

Jabil shares jumped 5.1% to $146.67 on Thursday.

Here are some other big stocks recording gains in today's session.

ProAssurance Corporation PRA shares jumped 47.8% to $22.98 after the company announced it will be acquired by The Doctors Company for $25.00 per share in cash. ARS Pharmaceuticals, Inc. SPRY gained 24.77% to $14.53 following fourth-quarter results. China Liberal Education Holdings Limited CLEU shares rose 19.8% to $2.42. Regencell Bioscience Holdings Limited RGC jumped 19.5% to $36.77. Capricor Therapeutics, Inc. CAPR rose 13.7% to $13.90 following strong quarterly results. Titan Machinery Inc. TITN gained 12.9% to $16.63 following strong quarterly sales. Carvana Co. CVNA gained 9.9% to $193.50 after Piper Sandler upgraded the stock from Neutral to Overweight.. Gambling.com Group Limited GAMB shares rose 9.4% to $13.65

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CAPR_OUT_11 [2025-03-20 14:30:25 -0400] 900 Bytes | 288 tokens | Cum: 2166 tkns (27.07% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-21T18:00:00Z - Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight
B2 - 2024-10-17T10:00:00Z - Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
B3 - 2024-10-01T18:08:45Z - Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
B4 - 2024-07-02T12:01:01Z - Unveiling 6 Analyst Insights On Capricor Therapeutics
B5 - 2024-06-25T14:30:00Z - CORRECTION: Capricor Therapeutics
B6 - 2024-06-25T12:30:00Z - Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CAPR_OUT_13 [2025-03-20 14:30:29 -0400] 774 Bytes | 211 tokens | Cum: 2379 tkns (29.74% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/21/3030613/0/en/Cell-and-Gene-Therapies-in-Rare-Disorders-Market-to-Skyrocket-Across-the-7MM-During-the-Forecast-Period-2025-2034-DelveInsight.htmlThe cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CAPR_OUT_15 [2025-03-20 14:30:31 -0400] 831 Bytes | 223 tokens | Cum: 2655 tkns (33.19% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-19 8-K Item 2.02 Results of Oper and Fin Cond.

On March 19, 2025, Capricor Therapeutics, Inc., a Delaware corporation (the Company), issued a press release announcing its financial results for the quarter and full year ended December 31, 2024. A copy of the press rele...

S3 - 2025-03-04 8-K Item 7.01 Regulation FD Disclosure.

On March 4, 2025, Capricor Therapeutics, Inc. (the Company or Capricor) issued a press release announcing announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) seeking full ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CAPR_OUT_17 [2025-03-20 14:30:37 -0400] 1000 Bytes | 239 tokens | Cum: 2896 tkns (36.20% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02 Results of Operations and Financial Condition.

On March 19, 2025, Capricor Therapeutics, Inc., a Delaware corporation (the Company), issued a press release announcing its financial results for the quarter and full year ended December 31, 2024. A copy of the press release is being furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information under Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any of the Companys filings under the Exchange Act, unless expressly set forth as being incorporated by reference into such filing....

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CAPR_OUT_19 [2025-03-20 14:30:49 -0400] 6502 Bytes | 1981 tokens | Cum: 4978 tkns (62.22% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+---------------------+------------------------+-------------------------+------------------------+-------------------------+
| Volume: 2,121,779 | SMA50: 3.24% | Market Cap: 658.86M | Option/Short: Yes / Yes | Sales past 5Y: 434.62% | Sales Surprise: 215.98% |
+-------------------+---------------------+------------------------+-------------------------+------------------------+-------------------------+
| Avg Volume: 1.15M | SMA200: 26.98% | Shs Outstand: 40.33M | Short Float: 20.45% | Employees: 102 | EPS Surprise: 5.88% |
+-------------------+---------------------+------------------------+-------------------------+------------------------+-------------------------+
| Rel Volume: 2.49 | Perf Week: 13.29% | Shs Float: 39.94M | Short Ratio: 7.12 | Debt/Eq: 0.07 | P/E: - |
+-------------------+---------------------+------------------------+-------------------------+------------------------+-------------------------+
| RSI (14): 54.74 | Perf Month: -3.98% | Inst Own: 39.05% | Short Interest: 8.17M | Sales Y/Y TTM: 65.33% | Earnings: Mar 19 AMC |
+-------------------+---------------------+------------------------+-------------------------+------------------------+-------------------------+
| ATR (14): 1.29 | Perf Quarter: 4.39% | Insider Own: 12.16% | Beta: 4.60 | ROE: -102.63% | |
+-------------------+---------------------+------------------------+-------------------------+------------------------+-------------------------+
| SMA20: 6.90% | Index: RUT | Insider Trans: 102.48% | Sales Q/Q: -63.44% | ROI: -47.07% | |
+-------------------+---------------------+------------------------+-------------------------+------------------------+-------------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by Marban Linda (CHIEF EXECUTIVE OFFICER) on 2025-03-03
- Common Stock: 25000 shares at $1.39 (D)
- Common Stock: 12500 shares at $0 (D) Footnote: Transferred to reporting person's ex-spouse pursuant to settlement in divorce proceeding.
- Stock Option (Right to Buy): 25000 shares at $0 (D)

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by Bergmann Anthony (CHIEF FINANCIAL OFFICER) on 2025-03-03
- Common Stock: 2500 shares at $1.39 (D)
- Stock Option (Right to Buy): 2500 shares at $0 (D)

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by DUNBAR GEORGE W JR (Unknown Title) on 2025-03-03
- Common Stock: 750 shares at $1.39 (D)
- Stock Option (Right to Buy): 750 shares at $0 (D)

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by Litvack Frank (Unknown Title) on 2025-03-03
- Common Stock: 25000 shares at $1.39 (D)
- Common Stock: 2543 shares at $13.67 (D) Footnote: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on March 3, 2025 of $13.67. The options would otherwise expire on March 3, 2025, pursuant to their terms.
- Stock Option (Right to Buy): 25000 shares at $0 (D)

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by COLLIER EARL M JR (Unknown Title) on 2025-02-27
- Common Stock: 750 shares at $1.39 (D)
- Stock Option (Right to Buy): 750 shares at $0 (D)

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by Kelliher Mike (Unknown Title) on 2025-01-02
- Stock Option (Right to Buy): 11940 shares at $0 (D)
- Stock Option (Right to Buy): 1440 shares at $0 (D)
- Stock Option (Right to Buy): 5750 shares at $0 (D)

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by Marban Linda (CHIEF EXECUTIVE OFFICER) on 2025-01-02
- Stock Option (Right to Buy): 210000 shares at $0 (D)
- Stock Option (Right to Buy): 34962 shares at $0 (D)

Inside Trans: CAPRICOR THERAPEUTICS, INC. (CAPR) by Krasney Karen (EVP, GENERAL COUNSEL) on 2025-01-02
- Stock Option (Right to Buy): 60000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: Capricor Therapeutics Inc
Market Cap: 563826859.2
Shares Outstanding: 45469908
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 23228045.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -34112672.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 14.6882
Average Volume: 1461669.13
30-Day High: 15.8
30-Day Low: 11.61

[Detailed Financials: Q3 2024]
- Total Assets: $92,951,613.0
- Total Liabilities: $24,686,654.0
- Total Equity: $68,264,959.0
- Current Assets: $85,823,371.0
- Current Liabilities: $20,475,506.0

[Income Statement: Q3 2024]
- Revenue: $2,261,642.0
- Net Income: $-12,556,728.0
- Operating Income: $-13,009,880.0
- Earnings Per Share (EPS): -0.38

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $57,689,039.0

[Detailed Financials: Q2 2024]
- Total Assets: $38,277,453.0
- Total Liabilities: $26,775,147.0
- Total Equity: $11,502,306.0
- Current Assets: $30,669,223.0
- Current Liabilities: $22,354,779.0

[Income Statement: Q2 2024]
- Revenue: $3,971,438.0
- Net Income: $-10,999,782.0
- Operating Income: $-11,591,219.0
- Earnings Per Share (EPS): -0.35

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $4,473,716.0
==== END OF FINANCIAL REPORT ====

Now we've reached the end of the analysis.
You are now requested to make a summary analysis.
Please don't explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.
Please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]
1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CAPR_OUT_21 [2025-03-20 14:30:51 -0400] 561 Bytes | 131 tokens | Cum: 5348 tkns (66.85% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CAPR_IN_23 [2025-03-20 14:30:52 -0400] 126 Bytes | 29 tokens | Cum: 5387 tkns (67.34% of 8k)
==========================================================================

====================================
[2025-03-20 11:30:52] # Analysis Completed
Elapsed Time: 45.98 seconds